Putting Technologies through Their Paces
Structural genomics marries the high throughput sensibilities of genomics with the more contemplative process of structural biology. Structural proteomics, depending on whom you ask, is either the same process, or an offshoot that focuses on function. The PSI has largely fixated on maximizing "fold space" coverage without regard to biological significance. International efforts have eschewed that approach, elevating biology over coverage. Whatever the focus, structural biology pipelines initially constricted every step of the process.
"We needed better strategies at all steps-cloning, expression, purification, crystallization, and structure determination," says Aled Edwards, director of the Structural Genomics Consortium (SGC), an international effort with labs in Canada, the UK, and Sweden. "Every process needed improvement."
Because each protein is "idiosyncratic," Edwards says, what works for one may not work for another. Simply relying on anecdotal advice from the biologist down the Proteomics "
In terms of technology, there are, for the first time, a whole group of very talented people coming together to optimize structure-determination pipelines as part of their goal.
hall is unlikely to work. "There are thousands of new technologies," adds Edwards. "Most will be doorstops in five years. But of all these many, many, many technologies, which are actually useful?"
The solution, he says, is to put these technologies through their paces in a controlled fashion. "That's what the field is doing," he says, "looking at the panoply of technologies, seeing which work, so you don't end up chasing your tail." Importantly, the community archives that knowledge in searchable public databases like TargetDB and PepcDB, which track not only what works, but also what doesn't.
Earlier this year members of the SGC (including Edwards) and 13 other structural genomics facilities around the world published their collective wisdom in a paper entitled "Protein production and purification" (Nat Methods, 5:147-53, 2008) . Andrzej Joachimiak, director of the Midwest Center for Structural Genomics (MCSG), calls the paper "a Maniatis manual for protein purification." Edwards, who was corresponding author, says the report represents "the final UN-negotiated solution," a probability-based consensus protocol for all protein jocks, not just structural biologists.
From Bad Media, a Breakthrough
The protocol contains such suggestions as developing multiple distinct constructs for each target; using ligation-independent cloning (commercialized as Clontech's In-Fusion 2.0 PCR Cloning kits); and the unified use of expression tags for easy purification with robots such as GE Healthcare's AKTA-express.
Another tip: try F. William Studier's autoinduction media (available from EMD Biosciences as Novagen Overnight Express.). "It is a technique everyone should be using," says Edwards.
Recombinant protein expression in bacteria is commonly controlled via the lactose control circuit. Place a lac operator in front of a gene of interest, and the gene will remain silent until you add the allolactose analog, IPTG. But IPTG must be added at just the right moment, and different cultures grow at different rates. "How do you get all the cultures growing at the same rate and at the same time to get optimal expression of these proteins in parallel?" asks Studier, of the Brookhaven National Laboratory.
In trying to solve that problem, Studier observed that some of his cultures induced on their own, without IPTG. He discovered that one of his media components was contaminated with trace lactose. Making use of this observation, Studier first designed a rich formulation in which cultures could grow to high optical density (OD) but never induce (noninducing medium). He then developed a precise blend of glucose, lactose, and glycerol in which the cells autoinduce upon hitting log phase. And they would do so while cranking out protein at higher levels than usual, because the cells can grow to much greater densities-up to OD 20, compared to OD 3 in Luria broth. "So all you have to do is grow 96 cultures in noninducing medium, then inoculate those into autoinducing medium, grow overnight, and collect induced cultures in the morning," he says.
Biophysical Considerations
It's not enough to express a protein; it also must be soluble, and properly folded. At the Joint Center for Structural Genomics (JCSG) researchers employ a battery of methods to ensure desirable biophysical properties are met, says director Ian Wilson. Size-exclusion chromatography indicates whether the protein is soluble or aggregating. SDS-PAGE reveals protein purity. And deuteriumexchange mass spectrometry highlights disordered regions that could cause trouble downstream. "You label for a few seconds with deuterium, quench at low pH, digest with protease, and look for which regions are disordered by how much it is exchanging with the deuterium in the solution," Wilson explains. "Only the disordered regions incorporate deuterium, because it is so fast." Such data can be invaluable. Brian Kobilka of Stanford University, who solved the structure of the beta-2 adrenergic receptor, found (via separate methods) that a loop between transmembrane domains 5 and 6 was "floppy," inhibiting crystallization. His team overcame that via parallel approaches, one involving an antibody against the C-termini of these two helices, and the other, with Ray Stevens of the Scripps Research Institute, replacing that loop with a stable T4 lysozyme domain.
Others optimize structural work by tweaking protein length or surface chemistry. Researchers at the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France, site of the European Synchrotron Radiation Facility (ESRF), use a biotinylatable tag in their library construction and screening procedures to find soluble domains, says facility director Stephen Cusack.
Researchers at the MCSG, JCSG, and SGC improve crystal formation using reductive methylation and limited proteolysis. The former alters protein surface chemistry to allow different crystal packing and improve diffraction properties, while the latter removes disordered regions in situ. Both have been tested on large numbers of proteins, says Joachimiak-400 in the case of reductive methylation, yielding 30 structures that were otherwise unattainable.
Accelerating NMR
Structure determination by NMR has also benefited from 'omics efforts. HIFI-NMR, a "reduced dimensionality" approach developed at the PSI-2 Center for Eukaryotic Structural Genomics (CESG), reduces the time required to acquire spectral assignment data by a factor of 10, says principal investigator John Markley of the University of Wisconsin, Madison. Instead of blindly collecting data by standard methods, this approach leverages prior information at each step to get the job done in the most efficient manner.
Using NMR chemical shift data from the Northeast Structural Genomics Consortium, Yang Shen and Ad Bax from the National Institutes of Health, with Oliver Lange and David Baker at the University of Washington, validated a novel computational method (CS-ROSETTA) that predicts protein structure from chemical shift data. Their new approach thereby eliminates the need for both side-chain assignments and one of NMR's lengthiest steps, nuclear Overhauser effect experiments.
"There are algorithms available to predict chemical shifts from structure," says Markley. "[Bax] is using [CS-ROSETTA] to go the other way-from the chemical shifts you get a starting approximation of what the 3D conformation of the protein is." Then, using Baker's ROSETTA energetics algorithm, the software computes a likely final structure. In March, Bax and Baker applied CS-ROSETTA to 25 protein sequences; they estimated it can cut the structure-generation time by 50 percent.
Robotics
As with any 'omics enterprise, automation and robotics are integral to structural proteomics. HWI researchers have developed robotics Such automation means researchers can do more with less, and more accurately. "When I was a postdoc, I would set up crystallization droplets of 20 to 30 μl. Now we use 200 to 500 nl," says Joachimiak.
Crystallization robots are available from Rigaku and Fluidigm, among others. Joachimiak uses TTP LabTech's mosquito. So does Joel Sussman, director of the Israel Structural Proteomics Center and coeditor of Structural Proteomics and Its Impact on the Life Sciences (World Scientific, 2008) . In fact Sussman's lab is extensively automated, with robots for cloning, protein purification, and crystal visualization. At ESRF, where Sussman's team runs diffraction experiments, robots even mount their crystals into the beamline.
According to Paul Adams, head of the Berkeley Center for Structural Biology, automounting robots are especially useful for screening to see which crystals diffract best. Traditionally, "It would take a long time to put just one sample in front of the beam," he says. "If you can put the samples into a container and have a robot that can do that for you, you can speed it up and have less error."
Eukaryotic Troubles
Structural genomics centers have deposited over 6,600 structures in PDB. Yet challenges remain. Of 25,662 targets selected at the JCSG, 20,865 have been cloned, 20,546 expressed, 1,337 crystallized, and 686 solved-a 3.3 percent success rate. The New York SGX Research Center for Structural Genomics puts up comparable numbers: 486 structures from 8,849 selected targets (5.5 percent).
Eukaryotic proteins represent a particular challenge. For a variety of reasons, including posttranslational modifications, size, and domain structure, eukaryotic proteins are tougher nuts to crack than prokaryotic ones. As of June 1, 2008, the 10 PSI-2 centers have solved 1,716 protein structures, but just 197 of those are eukaryotic; the rest are either prokaryotic (1,500) or viral (19) .
"Quite often proteins require glycosylation to be made properly," says Ray Owens, director of the Oxford Protein Production Facility (OPPF), Oxford, UK. "So you cannot make them in E. coli. They need to be made in eukaryotic cells, which will authentically glycosylate them." OPPF researchers use transient transfection of human embryonic kidney (HEK293) cells. Because most glycoproteins are secreted, purification is a snap: just collect the supernatant. The problem, Owens says, is "the chemical heterogeneity of the glycoproteins." To skirt that issue team members use inhibitors like kifunensine to freeze glycoprotein sugar chains in a more homogeneous form, and endoglycosidases to pare these glycans back.
CESG researchers use a cell-free eukaryotic wheat germ extract from CellFree Sciences for their protein expression. "We find that we get roughly twice the number of successful targets produced by wheat germ extract than with E. coli," says Markley. It is also faster, less expensive, and involves easier protein purification, because sufficient protein for a structure determination is isolated from milliliter reactions, rather than in liter quantities of cells.
Membrane Proteins
Membrane proteins also present unique structural challenges, says Scripps' Stevens. First, because the membrane represents such a small fraction of total cellular volume, they are present at relatively low levels. More important, the membrane itself is integral to their structure. "We have to solubilize them, which puts them in a very unstable state," he says.
Yet detergent interferes with the protein packing that is essential to crystallization. Stevens has developed or implemented several techniques to work with membrane proteins, including a high throughput "lipidic cubic phase" crystallization process first developed by Martin Caffrey of the University of Limerick, Ireland, that was key to solving the beta-2 adrenergic receptor structure.
Researchers at the New York Consortium on Membrane Protein Structure (NYCOMPS), a PSI-2 specialized center, have alternative methods, says director Wayne Hendrickson of Columbia University. "We have developed a pipeline process analogous to the kind that has been effective at large-scale centers for soluble proteins to produce membrane proteins and analyze them by crystallography and NMR," he says.
For instance, the consortium uses ultraviolet absorbance and light scattering to test which detergents work best and which proteins are in the proper oligomeric forms. More recently, they developed a generic antibody-based approach to extensively incorporate selenomethionine residues into protein complexes, key to solving X-ray diffraction "phase problems."
Using tools such as these, NYCOMPS researchers have produced over three thousand membrane proteins in the past year, resulting in five structures, with another seven or eight "in determination." "We are very much in early stages," Hendrickson says.
And despite the thousands of structures pouring out of high throughput labs around the world, so, it is safe to say, is structural proteomics in general.
